Allie Maffit

Allie Maffit

Auto-generated profile, based on publicly available information

Allie Maffit

Pediatric Hematology/Oncology, Oregon Health & Science University, Portland, OR 97239

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ALAdam J. Lamble
Adam J. Lamble
YKYoko Kosaka
Yoko Kosaka
TLTed Laderas
Ted Laderas
AMAllie Maffit
Allie Maffit
AKAndy Kaempf
Andy Kaempf
ELEvan F. Lind
Evan F. Lind
Significance: Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with a 5-y survival of 29%. Immunotherapy is based on the premise that tumors suppress the immune system. We investigated the status of T cell immunity in AML at the time of diagnosis. We found a significant association between T cell percentage in the bone marrow and overall survival in newly diagnosed AML patients. When we evaluated the T cells from the bone marrow of patients with AML, one-third displayed profound functional impairment. Most of these compromised T cells, however, could be rescued using checkpoint inhibitors. Our results support the development of immune checkpoint therapy to combat this deadly disease.